Conditionnement : 5g
Synonyms: Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex
| Description | HP-β-CD (Hydroxypropyl betadex) is a water-soluble cyclodextrin derivative obtained by hydroxypropylation of β-cyclodextrin. HP-β-CD serves as a drug delivery carrier that enhances stability and bioavailability. |
| Targets & IC50 | leukemia cell:3.86–10.09 mM, SKOV3 cells:1.94 μM |
| In vitro | Methods: Cheliensisin A native compound and its HP-β-CD inclusion complex (compound:HP-β-CD molar ratio 1:2) were added to SW1116, SMMC-7721, and HEK293T cells. Drug concentration gradient: 0–100 μM. Treatment duration: 24 hours. Cell viability was assessed using the MTT assay. Results: The inclusion complex significantly enhanced cytotoxicity against tumor cells. For SW1116 cells, the IC₅₀ of the cheliensisin A inclusion complex decreased from 93.2 to 51.4 μM. The inclusion complex also exhibited increased toxicity toward HEK293T cells. [1] Methods: Human aortic smooth muscle cells (HASMCs) were treated with HP-β-CD (6, 8, 10 mg/mL) for 24 h, followed by Western blot analysis of apoptosis markers. Results: HP-β-CD dose-dependently inhibited VSMC apoptosis. [2] |
| In vivo | Methods: Male C57BL/6J mice were used in a PCSK9/angiotensin II (AngII)-induced AAA model. HP-β-CD (200 µl/mouse) was administered intraperitoneally twice weekly starting at the initiation of AngII infusion, continuing for 4 weeks. Results: HP-β-CD significantly reduced the maximum diameter of the abdominal aorta and the incidence of AAA, while also mitigating elastin degradation and VSMC apoptosis. [2] |
| Synonyms | Hydroxypropyl-β-cyclodextrin, Hydroxypropyl betadex |
| Molecular Weight | 1541.547 |
| Formula | C63H112O42 |
| Cas No. | 128446-35-5 |
| Smiles | CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)O[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |
| Relative Density. | 1.05 g/cm3 at 20.3℃ |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 45.00 mg/mL (29.19 mM), Sonication is recommended.  H2O: 50.00 mg/mL (32.43 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (1.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO/H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
